{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T17:52:04Z","timestamp":1771005124036,"version":"3.50.1"},"reference-count":21,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2009,7,7]],"date-time":"2009-07-07T00:00:00Z","timestamp":1246924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Protective co\u2010therapy is recommended in NSAID users with GI risk factors, but adherence is poor.<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold> To assess the proportion of NSAID users receiving co\u2010therapy and strategies to improve adherence.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Arthritis patients \u226550\u2003years of age received etoricoxib or diclofenac in a double\u2010blind randomized trial. Reminders that high\u2010risk patients (age\u2003\u2265\u200365; previous ulcer\/haemorrhage; corticosteroid, anticoagulant, aspirin use) should receive co\u2010therapy were given at study initiation. Free PPI was provided. An intervention midway through the study included a written reminder and required written response regarding co\u2010therapy.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> 16\u2003244\/23\u2003504 (69%) patients had GI risk factors. Pre\u2010intervention, co\u2010therapy was most common with previous ulcer\/haemorrhage [706\/1107 (64%)] and 3\u20134 risk factors [331\/519 (64%)]. In the 10\u2003026 patients enrolled pre\u2010intervention and remaining in the study \u22656\u2003months after, co\u2010therapy in high\u2010risk patients increased from 2958\/6843 (43%) to 4177\/6843 (61%) (difference\u2003=\u200318%; 95% CI 16%,19%). The increase was greater outside the US (22%; 19%,24%) than in the US (15%; 13%,17%).<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Less than 50% of NSAID users with GI risk factors are given protective co\u2010therapy \u2013 even if prescribers are given reminders and cost is not an issue. Direct communication requiring written response significantly increased adherence to guidelines, but achieving higher levels of adherence will require additional strategies.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2009.04090.x","type":"journal-article","created":{"date-parts":[[2009,7,7]],"date-time":"2009-07-07T06:37:44Z","timestamp":1246948664000},"page":"767-774","source":"Crossref","is-referenced-by-count":36,"title":["Prescription rates of protective co\u2010therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines"],"prefix":"10.1111","volume":"30","author":[{"given":"L.","family":"LAINE","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"CONNORS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. R.","family":"GRIFFIN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. P.","family":"CURTIS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"KAUR","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. P.","family":"CANNON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,9,3]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.3.337"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.983"},{"issue":"4","key":"e_1_2_6_4_2","first-page":"S30","article-title":"The role of proton pump inhibitors in NSAID\u2010associated gastropathy and upper gastrointestinal symptoms","volume":"3","author":"Laine L","year":"2003","journal-title":"Rev Gastroenterol Disord"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-198904000-00009"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200004)43:4<917::AID-ANR25>3.0.CO;2-F"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02599040"},{"issue":"2","key":"e_1_2_6_8_2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/0002-9343(88)90250-1","article-title":"Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis","volume":"84","author":"Bloom BS","year":"1986","journal-title":"Am J Med"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1998.00588.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.04.010"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.02200.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03905.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002296"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2007.03.011"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.06.058"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.08.003"},{"issue":"2","key":"e_1_2_6_18_2","first-page":"A\u201036\u20107","article-title":"Use of GI protective agents and COX\u20102 selective inhibitors in 14,394,624 U.S. patients taking NSAIDs","volume":"126","author":"Laine L","year":"2004","journal-title":"Gastroenterology"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.08.016"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01595.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2006.05.024"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69666-9"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2009.04090.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2009.04090.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T20:14:04Z","timestamp":1697228044000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2009.04090.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,3]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1111\/j.1365-2036.2009.04090.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2009.04090.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,3]]}}}